Mycophenolate mofetil for myasthenia gravis: a clear and present controversy | Zendy

Chad Heatwole | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mycophenolate mofetil for myasthenia gravis: a clear and present controversy

Author(s) -

Chad Heatwole

Publication year - 2008

Publication title -

neuropsychiatric disease and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.819

H-Index - 67

eISSN - 1178-2021

pISSN - 1176-6328

DOI - 10.2147/ndt.s3309

Subject(s) - medicine , prednisone , myasthenia gravis , mycophenolate , placebo , clinical trial , randomized controlled trial , population , intensive care medicine , alternative medicine , transplantation , pathology , environmental health

Mycophenolate mofetil (MMF) has been used to treat myasthenia gravis (MG) for over 10 years. MMF's use in the MG population stems from its theoretical mechanism of action and the medical literature that supports its benefit in MG patients. Recently, two large, double-blinded, placebo-controlled, randomized clinical trials were initiated to study the effectiveness of MMF for MG. One of these studies found no benefit in taking MMF with 20 mg of prednisone as compared to taking prednisone alone, while the other study demonstrated no advantage in taking MMF against placebo during a 36-week prednisone taper. This article critically reviews the medical literature on MMF's use in MG and suggests further research avenues on this topic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research